Table 1.
Main characteristics of the eligible studies.
| Study | Study region | Duration | Cancer type | TNM stage | Follow-up (months) | Number | Technology | PRDX1-high (%) | Analysis method | HR (95% CI) | Language | Quality |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sieńko J 2019 | Poland | 2003-2010 | OC | I-IV | Mean 60.23 | 55 | IHC | 11 (20.0%) | Multivariate | OS: 3.571 (1.408-9.091) DFS: 2.632 (1.111-6.250) |
English | 8 |
| Cai AL (T) 2018 | China | 2007-2010 | OSC | I-III | Mean 63 | 110 | IHC | 66 (60.0%) | Multivariate | OS: 1.938 (1.197-3.138) DFS: 1.845 (1.191-2.856) |
English | 7 |
| Cai AL (V) 2018 | China | 2007-2010 | OSC | I-III | Mean 63 | 90 | IHC | 59 (65.6%) | Multivariate | OS: 2.261 (1.288-3.970) DFS: 2.213 (1.374-3.564) |
English | 7 |
| Li HX 2018 | China | 2009-2012 | CRC | I-IV | NR | 60 | IHC | 42 (70.0%) | Univariate | OS: 1.754 (1.010-3.046) | English | 6 |
| Zheng MJ 2018 | China | 2008-2012 | OC | I-IV | Up to 2017.9 | 101 | IHC | 17 (16.8%) | Multivariate | OS: 10.033 (1.956-51.462) | English | 8 |
| Yu W 2018 | China | 2008-2012 | GC | I-IV | NR | 189 | IHC | 127 (67.2%) | Multivariate | OS: 2.433 (1.429-4.132) DFS: 2.469 (1.456-4.184) |
English | 7 |
| Zhou J 2015 | China | 2004-2008 | CCA | I-IV | Median 16 | 88 | IHC | 53 (60.2%) | Multivariate | OS: 2.597 (1.114-6.061) DFS: 1.344 (0.603-2.994) |
English | 8 |
| Wu JP 2015 | China | 2005-2014 | ESCC | I-IV | NR | 144 | IHC | 96 (66.7%) | Multivariate | OS: 1.192 (0.616-2.304) | Chinese | 7 |
| Cai CY 2015 | China | 2008-2011 | PC | I-IV | Median 13.5 | 86 | IHC | 64 (74.4%) | Multivariate | OS: 3.162 (1.425-7.018) DFS: 4.805 (2.136-10.812) |
English | 8 |
| Xu DY 2014 | China | 2001-2003 | GC | I-IV | Median 30 | 120 | IHC | 70 (58.3%) | Univariate | OS: 1.769 (1.120-2.609) | Chinese | 6 |
| O'Leary PC (RPPA) 2014 | USA, Spain, Canada | NR | BC | I-III | NR | 712 | RPPA | 356 (50.0%) | Multivariate | OS:0.93 (0.66-1.31) DFS: 0.94 (0.65-1.35) |
English | 7 |
| O'Leary PC (TMA) 2014 | Sweden | 1987-1992 | BC | I-III | Median 11 | 442 | IHC | 221 (50.0%) | Multivariate | OS: 0.76 (0.56-1.03) DFS: 0.78 (0.52-1.16) |
English | 8 |
| Sun QK 2014 | China | 2006-2009 | HCC | I-IV | Median 24 | 76 | IHC | 56 (73.7%) | Multivariate | OS: 2.897 (1.355-6.194) DFS: 3.268(1.532-6.971) |
English | 8 |
| Li J 2013 | China | 2001-2009 | GBC | I-IV | NR | 80 | IHC | 42 (52.5%) | Multivariate | OS: 2.123 (1.266-3.562) | English | 7 |
| Yonglitthipagon P 2012 | Thailand | NR | CCA | NR | NR | 301 | IHC | 102 (33.9%) | Multivariate | OS: 0.662 (0.498-0.877) | English | 7 |
| Kim JH 2007 | USA | 1993-2002 | NSCLC | I | Median 70 | 90 | IHC | 60 (66.7%) | Multivariate | OS: 2.409 (1.290-4.498) DFS: 2.327 (1.312-4.128) |
English | 8 |
| Hoshino I 2007 | Japan | NR | ESCC | I-IV | NR | 114 | IHC | 41 (36.0%) | Univariate | OS: 0.640 (0.436-0.937) | English | 6 |
OC: ovarian cancer; OSC: osteosarcoma; CRC: colorectal cancer; GC: gastric cancer; CCA: cholangiocarcinoma; ESCC: esophageal squamous cell carcinoma; PC: pancreatic cancer; BC: breast cancer; HCC: hepatocellular carcinoma; GBC: gallbladder cancer; NSCLC: non-small cell lung cancer; OS overall survival; DFS: disease-free survival; HR: hazard ratio; CI: confidence interval; NR: none reported; T: Training cohort; V: Validation cohort; RPPA: reverse phase protein array; TMA: microarray; IHC: immunohistochemistry.